Ingenia Therapeutics (950260) stock
KOSDAQ · Biotechnology
As of Nov 16, 9:16 AM KST
- Market cap
- KRW 993.8 billion
- As of Nov 16, 2026
- P/E
- Not available
- Latest fiscal year
- P/B
- 75.17x
- Latest reported equity
- P/S
- Not available
- Latest fiscal year
- ROE
- Not available
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 993.8 billion
- As of Nov 16, 2026
- P/E
- Not available
- Latest fiscal year
- P/B
- 75.17x
- Latest reported equity
- P/S
- Not available
- Latest fiscal year
- ROE
- Not available
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
—
P/B
75.17x
P/S
—
Earnings and dividend metrics▾
Earnings
EPS
—
Earnings per share
BPS
KRW 267
Book value per share
ROE
—
Return on equity
- BPS — net assets divided by the number of shares. Each share is backed by KRW 267 of net assets.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| H1 2026Consolidated · Filed Aug 19, 2026 | KRW 6.7 billion | -KRW 6.7 billion | -KRW 6.1 billion | — |
- Year-to-date rows are cumulative from the start of the fiscal year.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 8.37%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 420 million
- Previous 20-day average 5.00%
- Net short position
- 0 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 605,518 shares
- As of Nov 13, 2026 · 1.22% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 8.37% | KRW 420 million |
| Nov 12, 2026 | 6.17% | KRW 360 million |
| Nov 11, 2026 | 11.22% | KRW 370 million |
| Nov 10, 2026 | 15.06% | KRW 850 million |
| Nov 9, 2026 | 4.64% | KRW 350 million |
| Nov 6, 2026 | 4.22% | KRW 220 million |
| Nov 5, 2026 | 1.29% | KRW 80 million |
| Nov 4, 2026 | 2.22% | KRW 170 million |
| Nov 3, 2026 | 1.85% | KRW 80 million |
| Nov 2, 2026 | 6.69% | KRW 180 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Material Management InformationNov 9, 2026English
- Technology or Regulatory ApprovalOct 27, 2026English
- Report on Major Holdings of Shares (General Form)Sep 29, 2026 · Major Holding ReportEnglish
- Technology or Regulatory ApprovalSep 28, 2026English
- Material Management InformationSep 28, 2026English
- [Amended] Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 25, 2026 · Insider Ownership Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 25, 2026 · Insider Ownership Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 25, 2026 · Insider Ownership Report
Filings with a published English version open in English; the rest link to the Korean original.
Ingenia Therapeutics (950260) stock information
KOSDAQ
Ingenia Therapeutics (950260) is listed on KOSDAQ. Its market capitalization is about KRW 993.8 billion. These figures are computed in-house from official filings and are reference information only.
Ingenia Therapeutics — frequently asked questions
- What is the market capitalization of Ingenia Therapeutics?
- 950260 has a market capitalization of about KRW 993.8 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.